- Home
- PHAT vs SABR Comparison
PHAT vs SABR Comparison
Compare PHAT & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHAT | SABR |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | 371 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 969.8M | 842.0M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PHAT | SABR |
|---|---|---|
| Price | $12.47 | $1.86 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $19.83 | $1.50 |
| AVG Volume (30 Days) | 1.0M | ★ 5.6M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 42.72 | ★ 283.56 |
| EPS | N/A | ★ 0.02 |
| Revenue | $175,110,000.00 | ★ $3,866,956,000.00 |
| Revenue This Year | $93.04 | $7.51 |
| Revenue Next Year | $58.91 | $3.46 |
| P/E Ratio | ★ N/A | $95.50 |
| Revenue Growth | ★ 216.93 | 7.46 |
| 52 Week Low | $7.61 | $0.81 |
| 52 Week High | $18.31 | $3.30 |
Technical Indicators
Market Signals| Indicator | PHAT | SABR |
|---|---|---|
| Relative Strength Index (RSI) | 67.90 | 47.86 |
| Support Level | $12.31 | $1.73 |
| Resistance Level | $13.26 | $1.99 |
| Average True Range (ATR) | 0.60 | 0.13 |
| MACD | 0.23 | -0.01 |
| Stochastic Oscillator | 98.60 | 28.72 |
Price Performance
Historical ComparisonAbout PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The marketplace segment represented 80% of total 2025 revenue and airline technology solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.